Transcript for Earning Call for the Quarter and Half Year ended on September 30, 2026

APTUS PHARMA LIMITED Date: 29th October 2026 The BSE Ltd Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001 SECURITY CODE: 544529 SCRIPT SYMBOL: APPL Subject: Transcript of Earnings Call for the quarter and half year ended September 30, 2026 Dear Sir/Madam, In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached transcript of the Q2 FY27 Earnings Call of Aptus Pharma Limited held on 26th October, 2026, for your information and record. The aforesaid information shall also be made available on the Company’s website at https://aptus- pharma.com/earnings-call-transcript_26-10-2026/ Kindly take the above information on record. Thanking you, Yours faithfully, For Aptus Pharma Limited Tejash Hathi Managing Director DIN: 03151221 Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM “Aptus Pharma Limited Q2 FY27 Earnings Conference Call” October 26, 2026 Management: Mr. Tejash Hathi – Managing Director Aptus Pharma Limited October 26th, 2026 Aptus Pharma Limited Q2 FY 2027 Earnings Conference Call October 26, 2026 Moderator: Good day and welcome to the Q2 FY 2027 conference call of Aptus Pharma Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing ‘*’ and then ‘0’ on your touch-tone phone. I now hand the conference over to Mr. Tejash Hathi. Thank you and over to you, sir. Tejash Hathi: Good evening, ladies and gentlemen, I am Tejash Hathi – Managing Director of Aptus Pharma Limited, and it is my pleasure to welcome you to today’s Earnings Conference Call. On behalf of Aptus Pharma Limited, I would like to extend a warm welcome to all our investors, shareholders, analysts, participants, and all ladies and gentlemen. Thank you for joining us for our Earnings Conference Call for the first half of the financial year 2026-2027. First of all, I would like to thank you for your continued interest in the Aptus Pharma and for taking the time to understand our business, our performance, and our future vision. Today, I will take you through our company’s journey, the opportunities we see in the Indian pharmaceutical industry, our financial performance for the half-year ended 30th September 2026, and the scalability of our business model and our long- term strategic vision. I also would like to explain how we are thinking about the next phase of our development and the priorities that will guide our decisions as we continue to expand. Let me begin with a brief introduction of Aptus Pharma Limited. Page 1 of 13 Aptus Pharma Limited October 26th, 2026 The company is a pharmaceutical company established in the year of 2010. We started as a local player and over a period of time have become a strong regional player and now, we are emerging as a nationally recognized pharmaceutical company. Aptus Pharma Limited has steadily developed its presence in the Indian pharmaceutical sector with a focus on pharmaceutical brand building, market development, and the distribution of quality healthcare products. Today, our portfolio comprises more than 300 formulations across multiple therapeutic segments. This includes acute, chronic, wellness, and OTC products. We believe this approach provides us with operational flexibility and allows us to develop our market presence without making large manufacturing investments at the initial stage of growth. Our network comprises more than 250 distributors and sub-distributors, while our products have retail availability exceeding 45k and are trusted by more than 10,000 honorable doctors. As outlined in our investor presentation, our business is organized around three important verticals. The first is our pharmaceutical formulation business, which remains the core of our operations and focuses on the prescription-based therapies. The second is our OTC and wellness vertical, which gives us an opportunity to participate in the consumer healthcare and complementary wellness categories. The third is our service vertical, through which we intend to develop international opportunities and gradually expand our presence beyond the domestic market. We are also evaluating how to strengthen our capabilities across the pharmaceutical value chain over time, including the development of manufacturing capabilities as part of our long-term strategy. Our broader objective is to evolve from our existing platform into a more integrated pharmaceutical business with a stronger domestic footprint and a global, gradually international presence. As a listed company, we understand that our responsibilities extend beyond growing revenue. We must also focus on profitability, governance, regulatory compliance, financial discipline, and the responsible use of capital. We believe that sustainable value creation comes from building a strong business step-by-step rather than pursuing expansion without considering the financial and operational implications. This philosophy will continue to guide our approach as Aptus Pharma enters into the next phase of growth. Page 2 of 13 Aptus Pharma Limited October 26th, 2026 Let me take a short review of the Indian pharmaceutical industry and the opportunities that we believe are relevant to Aptus Pharma. India has established itself as one of the world’s leading pharmaceutical markets and is widely recognized as the pharmacy of the world as our Honorable Prime Minister said. As highlighted in our investor presentation, India ranks third globally in pharmaceutical production by volume, supplies approximately 20% of global generic medicines and exports pharmaceutical products to more than 200 countries. These achievements reflect the strength of India’s pharmaceutical ecosystem, its manufacturing capabilities, its expertise in generic medicines, and its ability to serve a wide range of healthcare requirements. We believe that the Indian pharmaceutical industry’s long-term growth potential provides an encouraging environment for companies like Aptus that can combine market understanding with operational discipline and a sustainable business model. I will now discuss our financial performance for the first half of the Financial Year 2026-2027. We are pleased to report a strong performance for the half-year ended 30th September 2026, reflecting the growth of our business and the progress we made in expanding our operations. Our revenue from operations stood Rs 48.90 crore compared with Rs 14.38 crore in the corresponding half-year of the previous financial year. This represents substantial year-on-year growth and a significant increase in our operating scale. Our total income for the period was approximately Rs 48.96 crore. On the profitability front, our EBITDA stood at approximately Rs 7.68 crore, while our profit before tax was approximately Rs 6.83 crore and our profit after tax stood at approximately Rs 5.08 crore. We believe these results demonstrate the progress we have made during the reporting period and provide an encouraging foundation for our next phase of development. However, as management, we do not view the performance only through the lens of revenue growth. We also look at the relationship between revenue, profitability, working capital, and the resources required to support expansion. Revenue growth is an important indicator for the business momentum, but the objective is to convert the momentum into a sustainable, profitable and financially sound operating structure. Our focus will therefore remain on maintaining appropriate cost discipline, improving operating efficiency, and ensuring our expa [Showing first 8,000 characters — download PDF for full document]